Recent studies have implicated CD147 and CD44 in the modulation of the Wnt/β-catenin pathway [29] in metastatic prostate cancer, a property that is being investigated as a potential therapeutic strategy [22]. This evidence concerns the gene CD44 and metastatic prostate carcinoma.